O
Outi Kuittinen
Researcher at University of Oulu
Publications - 13
Citations - 1543
Outi Kuittinen is an academic researcher from University of Oulu. The author has contributed to research in topics: Autologous stem-cell transplantation & Mantle cell lymphoma. The author has an hindex of 9, co-authored 13 publications receiving 1351 citations. Previous affiliations of Outi Kuittinen include Oulu University Hospital.
Papers
More filters
Journal ArticleDOI
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Christian H. Geisler,Arne Kolstad,Anna Laurell,Niels Smedegaard Andersen,Lone Bredo Pedersen,Mats Jerkeman,Mikael Eriksson,Marie Nordström,Eva Kimby,Anne Marie Boesen,Outi Kuittinen,Grete F. Lauritzsen,Herman Nilsson-Ehle,Elisabeth Ralfkiaer,Måns Åkerman,Mats Ehinger,Christer Sundström,R. Langholm,Jan Delabie,Marja-Liisa Karjalainen-Lindsberg,Peter de Nully Brown,Erkki Elonen +21 more
TL;DR: Intensive immunochemotherapy with in vivo purged stem cell support can lead to long-term progression-free survival of MCL and perhaps cure.
Journal ArticleDOI
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
Francesco d'Amore,Thomas Relander,Grete F. Lauritzsen,Esa Jantunen,Hans Hagberg,Harald Anderson,Harald Holte,Anders Österborg,Mats Merup,Peter de Nully Brown,Outi Kuittinen,Martin Erlanson,Bjørn Østenstad,Unn-Merete Fagerli,Ole V. Gadeberg,Christer Sundström,Jan Delabie,Elisabeth Ralfkiaer,Martine Vornanen,Helle Toldbod +19 more
TL;DR: Dose-dense induction followed by HDT/ASCT was well tolerated and led to long-term PFS in 44% of treatment-naive patients with PTCL, which represents an encouraging outcome, particularly considering the high median age and adverse risk profile of the study population.
Journal ArticleDOI
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
Christian H. Geisler,Arne Kolstad,Anna Laurell,Riikka Räty,Mats Jerkeman,Mikael Eriksson,Marie Nordström,Eva Kimby,Anne Marie Boesen,Herman Nilsson-Ehle,Outi Kuittinen,Grete F. Lauritzsen,Elisabeth Ralfkiaer,Mats Ehinger,Christer Sundström,Jan Delabie,Marja-Liisa Karjalainen-Lindsberg,Peter de Nully Brown,Erkki Elonen +18 more
TL;DR: Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MipI (s-MIPI) predicted survival significantly better than the International Prognostic Index.
Journal ArticleDOI
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) : Prolonged remissions without survival plateau
Christian Winther Eskelund,Arne Kolstad,Mats Jerkeman,Riikka Räty,Anna Laurell,Sandra Eloranta,Karin E. Smedby,Simon Husby,Lone Bredo Pedersen,Niels Smedegaard Andersen,Mikael Eriksson,Eva Kimby,Hans Bentzen,Outi Kuittinen,Grete F. Lauritzsen,Herman Nilsson-Ehle,Elisabeth Ralfkiaer,Mats Ehinger,Christer Sundström,Jan Delabie,Marja-Liisa Karjalainen-Lindsberg,Christopher T. Workman,Christopher T. Workman,Christian Garde,Christian Garde,Erkki Elonen,Peter de Nully Brown,Kirsten Grønbæk,Christian H. Geisler +28 more
TL;DR: Even though the Nordic regimen is considered as a very good choice of regimen, it is recommended inclusion in prospective studies to explore the benefit of novel agents in the frontline treatment of MCL.
Journal ArticleDOI
Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant.
Niels Smedegaard Andersen,Lone Bredo Pedersen,Erkki Elonen,A. Johnson,Arne Kolstad,Kaarle Franssila,Ruth Langholm,Elisabeth Ralfkiaer,Måns Åkerman,Mikael Eriksson,Outi Kuittinen,Christian H. Geisler +11 more
TL;DR: The aim of the first Nordic mantle cell lymphoma protocol was to study the clinical significance of an augmented CHOP induction chemotherapy followed by high‐dose chemotherapy and autologous stem cell transplantation and to examine the prognostic significance of stem cell contamination rates in newly diagnosed patients with MCL.